Hit-to-lead studies:: The discovery of potent adamantane amide P2X7 receptor antagonists

被引：116

作者：

Baxter, A ^{[1
]}

Bent, J ^{[1
]}

Bowers, K ^{[1
]}

Braddock, M ^{[1
]}

Brough, S ^{[1
]}

Fagura, M ^{[1
]}

Lawson, M ^{[1
]}

McInally, T ^{[1
]}

Mortimore, M ^{[1
]}

Robertson, M ^{[1
]}

Weaver, R ^{[1
]}

Webborn, P ^{[1
]}

机构：

[1] AStraZeneca R&D Charnwood, Loughborough LE11 5RH, Leics, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 22期

关键词：

D O I：

10.1016/j.bmcl.2003.08.034

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A Hit-to-Lead optimisation programme was carried out on the adamantane high throughput screening hit I resulting in the discovery of a number of potent P2X(7) antagonists. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：4047 / 4050

页数：4

共 14 条

[1]

ALCARAZ L, BIOORG MED CHEM LETT, DOI DOI 10.1016/JBMCL200308033

[2] Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor [J].

Baraldi, PG ;

Nuñez, MD ;

Morelli, A ;

Falzoni, S ;

Di Virgilio, F ;

Romagnoli, R .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (08) :1318-1329

[3]

BAXTER A, Patent No. 9802189

[4] Overview of P2 receptors: Possible functions in immune cells [J].

Burnstock, G .

DRUG DEVELOPMENT RESEARCH, 2001, 53 (2-3) :53-59

[5]

Di Virgilio F, 2001, HANDB EXP PHARM, V151, P355

[6] The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes [J].

Gargett, CE ;

Wiley, JS .

BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 (08) :1483-1490

[7]

Gu B, 1998, BLOOD, V92, P946

[8]

Guile SD, 2001, PROGR MED CHEM, V38, P115, DOI 10.1016/S0079-6468(08)70093-6

[9] Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response [J].

Labasi, JM ;

Petrushova, N ;

Donovan, C ;

McCurdy, S ;

Lira, P ;

Payette, MM ;

Brissette, W ;

Wicks, JR ;

Audoly, L ;

Gabel, CA .

JOURNAL OF IMMUNOLOGY, 2002, 168 (12) :6436-6445

[10] Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].

Lipinski, CA ;

Lombardo, F ;

Dominy, BW ;

Feeney, PJ .

ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25

← 1 2 →